Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Drug-Drug Interaction Between THC and AEF0117
- Conditions
- Cannabis Abuse
- Interventions
- Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-oneDrug: Placebo
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 24
- Registration Number
- NCT06395688
Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 40
- Registration Number
- NCT05748405
- Locations
- 🇪🇸
Hospital del Mar Medical Research Institute (IMIM),, Barcelona, Catalonia, Spain
🇪🇸Sant Pau Memory Clinic, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸Unidad de Adultos con Síndrome de Down, Hospital de La Princesa, Madrid, Spain
Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 8
- Registration Number
- NCT05554926
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States
The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers
- Conditions
- Marijuana Abuse
- Interventions
- Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting conditionDrug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 24
- Registration Number
- NCT05451017
- Locations
- 🇺🇸
Substance Use Research Center, New York, New York, United States
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 333
- Registration Number
- NCT05322941
- Locations
- 🇺🇸
Cedar clinical research, Phoenix, Arizona, United States
🇺🇸CenExel CNR, Garden Grove, California, United States
🇺🇸UCLA Department of Psychiatry and Biobehavioral Sciences, Los Angeles, California, United States
- Prev
- 1
- 2
- Next
News
Aelis Farma's AEF0117 Fails Phase 2B Trial for Cannabis Use Disorder
• Aelis Farma's AEF0117 did not meet its primary endpoint of reducing cannabis use to one day or less per week in patients with moderate to severe cannabis use disorder (CUD). • The Phase 2B trial also failed to meet secondary endpoints, including complete cessation of marijuana use or reduction to two days or less per week. • Indivior, which had an option to license AEF0117, announced it does not currently expect to exercise this option due to the lack of separation from placebo in the trial. • AEF0117 was well-tolerated, with adverse events similar across treatment groups, including placebo, indicating no significant safety concerns.